Kala Pharmaceuticals investor relations material

Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company offers KPI-121 CL or KP201 CL, an ophthalmic solution that contains a contact lens to deliver drugs through the human eye's mucus layer directly into the anterior chamber of the eye. It also provides KPI-121 CL or KP201 CL in an ampul form.